Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats

Pharmacology

Volumn 89, Issue 1-2, 2012, Pages 74-82

  Han, Lei ^a,c   Li, Minggao ^a   Liu, Yongxue ^b   Han, Chunguang ^b   Ye, Ping ^c  

^a NAVY GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Atorvastatin; Cardiac aging; Peroxisome proliferator activated receptors

Indexed keywords

ATORVASTATIN; BETA GALACTOSIDASE; CATALASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYTOKINE; GELATINASE B; INTERLEUKIN 1BETA; MALONALDEHYDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG RECEPTOR BINDING; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

AGING; ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CELLS, CULTURED; GENE EXPRESSION REGULATION; HEART; HEPTANOIC ACIDS; INFLAMMATION MEDIATORS; MYOCARDIUM; OXIDOREDUCTASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PYRROLES; RATS; RATS, WISTAR; UP-REGULATION;

EID: 84862827158     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000335783     Document Type: Article

References (38)

1. McGeer PL, McGeer EG: Inflammation and the degenerative diseases of aging. Ann NY Acad Sci 2004; 1035: 104-116.
2. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP: Do statins reduce blood pressure?: A meta-analysis of randomized, controlled trials. Hypertension 2007; 49: 792-798.
3. Becker J, Delayre-Orthez C, Frossard N, Pons F: Regulation of inflammation by PPARs: A future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006; 20: 429-447.
4. Janeway C, Medzhitov R: Viral interference with IL-1 and Toll signaling. Proc Natl Acad Sci USA 2000; 97: 10682-10683.
5. Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, Caruso C: Innate immunity and inflammation in ageing: A key for understanding age-related diseases. Immun Ageing 2005; 2: 8.
6. Desvergne B, Wahli W: Peroxisome proliferator- activated receptors: Nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
7. Neve BP, Fruchart JC, Staels B: Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000; 60: 1245-1250.
8. Alvarez-Guardia D, Palomer X, Coll T, Serrano L, Rodriguez-Calvo R, Davidson MM, Merlos M, El Kochairi I, Michalik L, Wahli W, Vazquez-Carrera M: PPARbeta/delta activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim Biophys Acta 2011; 1811: 59-67.
9. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y: Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000; 87: 596-602.
10. Daynes RA, Jones DC: Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748-759.
11. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-793.
12. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NFkappaB and AP-1. J Biol Chem 1999; 274: 32048-32054.
13. Zhou YC, Waxman DJ: Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids. Environ Health Perspect 1998; 106(suppl 4):983-988.
14. Martin H: Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutat Res 2010; 690: 57-63.
15. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-1103.
16. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
17. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
18. Planavila A, Laguna JC, Vazquez-Carrera M: Atorvastatin improves peroxisome proliferator- activated receptor signaling in cardiac hypertrophy by preventing nuclear factorkappa B activation. Biochim Biophys Acta 2005; 1687: 76-83.
19. Ye P, Sheng L, Zhang C, Liu Y: Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Pharm Sci 2006; 9: 365-375.
20. Welder AA: A primary culture system of adult rat heart cells for the evaluation of cocaine toxicity. Toxicology 1992; 72: 175-187.
21. Zhang X, Azhar G, Furr MC, Zhong Y, Wei JY: Model of functional cardiac aging: young adult mice with mild overexpression of serum response factor. Am J Physiol Regul Integr Comp Physiol 2003; 285:R552-R560.
22. Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the adVanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996; 93: 3902-3907.
23. Michel JB, Heudes D, Michel O, Poitevin P, Philippe M, Scalbert E, Corman B, Levy BI: Effect of chronic Ang I-converting enzyme inhibition on aging processes. II. Large arteries. Am J Physiol 1994; 267:R124-R135.
24. Nguyen CT, Hall CS, Scott MJ, Zhu Q, Marsh J, Wickline SA: Age-related alterations of cardiac tissue microstructure and material properties in Fischer 344 rats. Ultrasound Med Biol 2001; 27: 611-619.
25. Muslin AJ: New insights into cardiac aging. Circulation 2009; 120: 1654-1656.
26. Cand F, Verdetti J: Superoxide dismutase, glutathione peroxidase, catalase, and lipid peroxidation in the major organs of the aging rats. Free Radic Biol Med 1989; 7: 59-63.
27. Inuzuka Y, Okuda J, Kawashima T, Kato T, Niizuma S, Tamaki Y, Iwanaga Y, Yoshida Y, Kosugi R, Watanabe-Maeda K, Machida Y, Tsuji S, Aburatani H, Izumi T, Kita T, Shioi T: Suppression of phosphoinositide 3-kinase prevents cardiac aging in mice. Circulation 2009; 120: 1695-1703.
28. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-1286.
29. Corman B, Duriez M, Poitevin P, Heudes D, Bruneval P, Tedgui A, Levy BI: Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA 1998; 95: 1301-1306.
30. Kreher P, Ristori MT, Corman B, Verdetti J: Effects of chronic angiotensin I-converting enzyme inhibition on the relations between ventricular action potential changes and myocardial hypertrophy in aging rats. J Cardiovasc Pharmacol 1995; 25: 75-80.
31. Leeuwenburgh C, Phaneuf S: Cytochrome c release from mitochondria in the aging heart: A possible mechanism for apoptosis with age. Am J Physiol Reg I 2002; 282:R423-R430.
32. Leeuwenburgh C, Judge S, Jang YM, Smith A, Hagen T: Age-associated increases in oxidative stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: Implications for the mitochondrial theory of aging. Faseb J 2005; 19: 419-421.
33. Nishimaru K: Aging-associated changes in cardiac function and their prevention. Clin Calcium 2008; 18: 935-940.
34. Csiszar A, Wang M, Lakatta EG, Ungvari Z: Inflammation and endothelial dysfunction during aging: Role of NF-kappaB. J Appl Physiol 2008; 105: 1333-1341.
35. Stice JP, Chen L, Kim SC, Jung JS, Tran AL, Liu TT, Knowlton AA: 17beta-Estradiol, aging, inflammation, and the stress response in the female heart. Endocrinology 2011; 152: 1589-1598.
36. Tikellis C, Thomas MC, Harcourt BE, Coughlan MT, Pete J, Bialkowski K, Tan A, Bierhaus A, Cooper ME, Forbes JM: Cardiac inflammation associated with a western diet is mediated via activation of RAGE by AGEs. Am J Physiol Endocrinol Metab 2008; 295:E323-E330.
37. Auwerx J: Regulation of gene-expression by fatty-acids and fibric acid-derivatives - An integrative role for peroxisome proliferator activated receptors - The Belgian Endocrine Society lecture 1992. Horm Res 1992; 38: 269-277.
38. Youssef J, Badr M: Role of peroxisome proliferator- activated receptors in inflammation control. J Biomed Biotechnol 2004; 2004: 156-166